PMV Pharma Q2 FY26 net loss narrows 14.73% to $18.09 million
PMVP•Program update and financing position
- Enrollment completed for the primary analysis in the Phase 2 PYNNACLE ovarian cancer cohort; initial accelerated-approval NDA filing targeted for Q1 2027.
Quarterly loss narrows as expenses decline
- PMV Pharmaceuticals posted a net loss of $18.09 million in the quarter ended June 30, 2026, narrowing from $21.21 million a year earlier.
- Operating loss improved to $18.88 million from $22.88 million, as operating expenses fell 17.47% to $18.88 million.
- Research and development expense dropped 20.24% to $14.68 million; general and administrative costs edged down 6.12% to $4.21 million.
- Interest income, net slid 53.37% to $788,000; cash, cash equivalents and marketable securities totaled $79.43 million at June 30, 2026.
Related News
Ultra Clean Holdings Inc Files For Common Stock Offering Of Up To $400 Million
UCTT•
TOMI Environmental net loss narrows 69% year-over-year to $(382,299) in Q2 FY26; revenue more than doubles 118% to $2.25 million
TOMZ•
